» Articles » PMID: 33808045

Computational Hypothesis: How Intra-Hepatic Functional Heterogeneity May Influence the Cascading Progression of Free Fatty Acid-Induced Non-Alcoholic Fatty Liver Disease (NAFLD)

Overview
Journal Cells
Publisher MDPI
Date 2021 Apr 3
PMID 33808045
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Non-Alcoholic Fatty Liver Disease (NAFLD) is the most common type of chronic liver disease in developed nations, affecting around 25% of the population. Elucidating the factors causing NAFLD in individual patients to progress in different rates and to different degrees of severity, is a matter of active medical research. Here, we aim to provide evidence that the intra-hepatic heterogeneity of rheological, metabolic and tissue-regenerating capacities plays a central role in disease progression. We developed a generic mathematical model that constitutes the liver as ensemble of small liver units differing in their capacities to metabolize potentially cytotoxic free fatty acids (FFAs) and to repair FFA-induced cell damage. Transition from simple steatosis to more severe forms of NAFLD is described as self-amplifying process of cascading liver failure, which, to stop, depends essentially on the distribution of functional capacities across the liver. Model simulations provided the following insights: (1) A persistently high plasma level of FFAs is sufficient to drive the liver through different stages of NAFLD; (2) Presence of NAFLD amplifies the deleterious impact of additional tissue-damaging hits; and (3) Coexistence of non-steatotic and highly steatotic regions is indicative for the later occurrence of severe NAFLD stages.

Citing Articles

Emodin induced hepatic steatosis in BALb/c mice by modulating the gut microbiota composition and fatty acid metabolism.

Xia X, He X, Huang J, Hou X, Lin C, Liu Y Front Pharmacol. 2025; 15():1516272.

PMID: 39776579 PMC: 11703826. DOI: 10.3389/fphar.2024.1516272.


A Quantitative Systems Pharmacology Model of Liver Lipid Metabolism for Investigation of Non-Alcoholic Fatty Liver Disease.

Rieger T, Allen R, Musante C Front Pharmacol. 2022; 13:910789.

PMID: 35928268 PMC: 9343875. DOI: 10.3389/fphar.2022.910789.


Applications of Quantitative Systems Pharmacology (QSP) in Drug Development for NAFLD and NASH and Its Regulatory Application.

Siler S Pharm Res. 2022; 39(8):1789-1802.

PMID: 35610402 PMC: 9314276. DOI: 10.1007/s11095-022-03295-x.

References
1.
Iozzo P, Turpeinen A, Takala T, Oikonen V, Solin O, Ferrannini E . Liver uptake of free fatty acids in vivo in humans as determined with 14( R, S)-[18F]fluoro-6-thia-heptadecanoic acid and PET. Eur J Nucl Med Mol Imaging. 2003; 30(8):1160-4. DOI: 10.1007/s00259-003-1215-0. View

2.
Zhang X, Guo Y, Song Y, Sun W, Yu C, Zhao X . Proteomic analysis of individual variation in normal livers of human beings using difference gel electrophoresis. Proteomics. 2006; 6(19):5260-8. DOI: 10.1002/pmic.200600006. View

3.
Listenberger L, Han X, Lewis S, Cases S, Farese Jr R, Ory D . Triglyceride accumulation protects against fatty acid-induced lipotoxicity. Proc Natl Acad Sci U S A. 2003; 100(6):3077-82. PMC: 152249. DOI: 10.1073/pnas.0630588100. View

4.
Berndt N, Holzhutter H . Dynamic Metabolic Zonation of the Hepatic Glucose Metabolism Is Accomplished by Sinusoidal Plasma Gradients of Nutrients and Hormones. Front Physiol. 2019; 9:1786. PMC: 6315134. DOI: 10.3389/fphys.2018.01786. View

5.
Ipsen D, Lykkesfeldt J, Tveden-Nyborg P . Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. Cell Mol Life Sci. 2018; 75(18):3313-3327. PMC: 6105174. DOI: 10.1007/s00018-018-2860-6. View